“Tyrosine”的搜索结果，显示 11-20 项，共有 9484 项

1. 血液科- 临床试验- 妙佑医疗国际

   This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

2. 血液科- 临床试验- 妙佑医疗国际

   This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...